Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

COPAXONE(r) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. In North America, COPAXONE(r) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA). COPAXONE(r) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

See additional important information at http://www.copaxone.com/pi/index.html <http://www.copaxone.com/pi/index.html> or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.

-more-

GA Mitoxantrone Combination/Page 4

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutic
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:6/1/2015)... 1, 2015  Research Solutions, Inc. (OTCQB: RSSS), a pioneer ... (STM) information for life science companies, academic institutions, and ... at the LD Micro Invitational being held on June ... Los Angeles . ... June 3rd at 9:30 a.m. Pacific time, with one-on-one ...
(Date:6/1/2015)... June 1, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic ... public offering of its common stock consisting of 1,475,506 ... to be sold by certain of its stockholders. In ... option to purchase up to an additional 590,202 shares ...
(Date:6/1/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... data from its Phase I/II clinical trial of  ... (GBM), the most common and deadly form of ...
Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8
... DIEGO , April 27 CareFusion Corporation (NYSE: CFN ) ... Thursday, May 6 following the close of trading on the New York Stock ... The company will host a webcast and ... ( 5 p.m. Eastern time ) to discuss the results for its third quarter, ...
... , April 27 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... provide a general business overview, as well as to discuss first quarter 2010 ... Eastern Time ( 2:00 p.m. Pacific Time ).  Financial results for the ... day. , , , ...
Cached Medicine Technology:CareFusion Will Host an Earnings Conference Call on May 6 to Discuss the Results for the Third Quarter of Fiscal 2010 2Onyx Pharmaceuticals Announces First Quarter 2010 Financial Results Teleconference and Webcast 2
(Date:6/1/2015)... 2015 The National Association of ... DSL, LSSBB (C), First Sergeant A Co., 15BSB , ... the Year Circle. She is recognized with this prestigious ... nation's leading networking organization exclusively for professional women, boasting ... Chapters. , “I'm pleased to recognize Sergeant Cornett with ...
(Date:6/1/2015)... 01, 2015 Carson Energy also announced ... investors IRA transactions. AdvantaIRA Trust, LLC is the country’s ... ability to fund positions using IRA’s does 2 things:, ... a project, even if there current cash position will ... funding source for Carson and their investors to be ...
(Date:6/1/2015)... 2015 The federal court overseeing hundreds ... the Case Management Order governing case selection for bellwether ... Amended Order which was issued in the U.S. District ... directs the parties to submit a Proposed Case Management ... outlines parameters and the process for selecting AbbVie-only plaintiffs ...
(Date:6/1/2015)... 2015 Atagi Plastic Surgery and Skin ... an Ultherapy® Ultra Treatment Provider by Ulthera, ... Aesthetics is one of only six practices in Colorado ... provider. , Atagi Plastic Surgery and Skin Aesthetics’ ... has led the practice to earn the distinction of ...
(Date:6/1/2015)... 01, 2015 Linda Kincaid, age 67, knew ... irregular heartbeat. At first she thought it was just a ... was much more than that. After going to the doctor, ... she felt afraid about what might happen to her. , ... are diagnosed with valve disease each year. Valve disease involves ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3
... Aurora Health Care ... bi-lateral knee replacement this morning. This first, ... helped to reach thousands of viewers. (Photo: ... the surgery, Aurora caregivers posted updates as "tweets" ...
... say , , THURSDAY, April 16 (HealthDay News) -- The ... blindness-causing macular edema in people with diabetes who have ... About 50 percent of people who have type 1 ... diabetes develop retinopathy, which is damage to the retina ...
... It first began as an idea to fight ... and in fact, Accents in Water remains the only ... today. Then, general public settings like restaurants, office buildings, ... a matter of time before custom interior designers and ...
... on Patients & Businesses Nationwide in Letter to the ... April 16 In a letter sent yesterday, a ... White House Office of Health Reform, the Centers for ... Health and Human Services to review and rescind the ...
... for laboratories, future growthMUNDELEIN, Ill., April 16 ... diagnostic instrument manufacturer and information systems developer, ... with BioReference Laboratories, Inc. BioReference Laboratories, purchases ... of XE-Series Automated Hematology Analyzers, Sysmex SP-1000 ...
... , April 16 The "Help is ... the week of April 20 - April 24 at various ... information on programs that provide prescription medicines for free or ... percent, above the national average of 8.5 percent, the Partnership ...
Cached Medicine News:Health News:Aurora Health Care Twitter-Surgery A Success 2Health News:Drug May Not Help Diabetes-Related Eye Damage 2Health News:Hospital Approved Residential Water Features Kill Harmful Airborne Bacteria 2Health News:84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare 'Competitive' Bidding Rule Before April 18 Deadline 2Health News:84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare 'Competitive' Bidding Rule Before April 18 Deadline 3Health News:84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare 'Competitive' Bidding Rule Before April 18 Deadline 4Health News:84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare 'Competitive' Bidding Rule Before April 18 Deadline 5Health News:BioReference Laboratories Partners With Sysmex America 2Health News:BioReference Laboratories Partners With Sysmex America 3Health News:Partnership for Prescription Assistance Prepared to Help Indiana Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Indiana Workers Hurt by Recession 3
The DELFIA Platewash is a general purpose microtitration plate and strip washer especially standardized for use with DELFIA diagnostic kits....
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... washers available to handle multiple ... assays. Embla 384 Cell washer ... been optimized to avoid cell ... compatible and have been integrated ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: